EA200970291A1 - Фармацевтическая композиция, содержащая розувастатин кальция - Google Patents

Фармацевтическая композиция, содержащая розувастатин кальция

Info

Publication number
EA200970291A1
EA200970291A1 EA200970291A EA200970291A EA200970291A1 EA 200970291 A1 EA200970291 A1 EA 200970291A1 EA 200970291 A EA200970291 A EA 200970291A EA 200970291 A EA200970291 A EA 200970291A EA 200970291 A1 EA200970291 A1 EA 200970291A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
calcium
composition containing
rosuvastatin calcium
containing rosuvastatin
Prior art date
Application number
EA200970291A
Other languages
English (en)
Other versions
EA014451B1 (ru
Inventor
Мария Вираг
Иидико Моностори
Original Assignee
Рихтер Гедеон Нирт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рихтер Гедеон Нирт. filed Critical Рихтер Гедеон Нирт.
Publication of EA200970291A1 publication Critical patent/EA200970291A1/ru
Publication of EA014451B1 publication Critical patent/EA014451B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Объектом настоящего изобретения является новая фармацевтическая композиция, содержащая аморфный розувастатин кальция и гидроксид магния, и/или ацетат кальция, или глюконат кальция, или глицерофосфат кальция, или гидроксид алюминия в качестве стабилизирующей добавки и один или более фармацевтически приемлемых наполнителей.
EA200970291A 2006-09-18 2007-09-11 Фармацевтическая композиция, содержащая розувастатин кальция EA014451B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0600728A HU227610B1 (en) 2006-09-18 2006-09-18 Pharmaceutical compositions containing rosuvastatin potassium
PCT/HU2007/000082 WO2008035128A1 (en) 2006-09-18 2007-09-11 Pharmaceutical compositions containing rosuvastatin calcium

Publications (2)

Publication Number Publication Date
EA200970291A1 true EA200970291A1 (ru) 2009-06-30
EA014451B1 EA014451B1 (ru) 2010-12-30

Family

ID=89987035

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970291A EA014451B1 (ru) 2006-09-18 2007-09-11 Фармацевтическая композиция, содержащая розувастатин кальция

Country Status (24)

Country Link
US (1) US8221788B2 (ru)
EP (1) EP2063868B1 (ru)
JP (1) JP5534812B2 (ru)
CN (1) CN101516349A (ru)
AR (1) AR062874A1 (ru)
AT (1) ATE489078T1 (ru)
AU (1) AU2007298751B2 (ru)
CA (1) CA2662919C (ru)
CY (1) CY1114533T1 (ru)
DE (1) DE602007010797D1 (ru)
DK (1) DK2063868T3 (ru)
EA (1) EA014451B1 (ru)
ES (1) ES2357263T3 (ru)
HR (1) HRP20110125T1 (ru)
HU (1) HU227610B1 (ru)
JO (1) JO2641B1 (ru)
ME (1) ME01944B (ru)
PL (1) PL2063868T3 (ru)
PT (1) PT2063868E (ru)
RS (1) RS51563B (ru)
SI (1) SI2063868T1 (ru)
TW (1) TWI454265B (ru)
UA (1) UA97489C2 (ru)
WO (1) WO2008035128A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
TR200800269A2 (tr) * 2008-01-15 2009-08-21 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Stabil farmasötik formülasyon ve hazırlama yöntemleri
KR101577083B1 (ko) 2008-01-28 2015-12-11 뷰티 펄 그룹 리미티드 골다공증을 예방 및 개선하기 위한 칼슘, 마그네슘, 아연, 및 비타민 ｄ3을 포함하는 배합물
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
SI2309992T1 (en) * 2008-06-27 2018-03-30 Krka, Tovarna Zdravil, D.D., Novo Mesto A pharmaceutical composition comprising a statin
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
EP2566465A2 (en) 2010-05-04 2013-03-13 Mahmut Bilgic Stable rosuvastatin formulations
CN101972260B (zh) * 2010-11-24 2012-05-02 天津市汉康医药生物技术有限公司 一种瑞舒伐他汀钙口服药物组合物
KR20200003219A (ko) * 2011-05-20 2020-01-08 아스트라제네카 유케이 리미티드 로수바스타틴 칼슘의 약학 조성물
CN102860994B (zh) * 2011-07-04 2016-01-20 石药集团中奇制药技术（石家庄）有限公司 一种瑞舒伐他汀钙片及其制备方法
IN2015DN01662A (ru) 2012-09-18 2015-07-03 Auspex Pharmaceuticals Inc
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN102908335B (zh) * 2012-11-19 2015-04-08 山东罗欣药业集团股份有限公司 一种瑞舒伐他汀钙组合物及其制备方法
CN103961354A (zh) * 2013-02-05 2014-08-06 深圳信立泰药业股份有限公司 一种稳定的瑞舒伐他汀钙药物组合物及其制备方法
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
CN103494788B (zh) * 2013-10-10 2015-08-05 齐晓彤 瑞舒伐他汀钙片的药物组合物及其制备方法
EA201791466A1 (ru) 2013-12-03 2017-11-30 Оспекс Фармасьютикалз, Инк. Способы получения соединений бензохинолина
WO2016076280A1 (ja) * 2014-11-11 2016-05-19 塩野義製薬株式会社 光に対して不安定な薬物を含有する多層錠剤
CN104523650B (zh) * 2014-12-20 2017-04-12 山东新时代药业有限公司 一种含有瑞舒伐他汀钙的胶囊
PL3265085T3 (pl) 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) * 2015-04-24 2017-03-15 大原薬品工業株式会社 ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
CN104840964B (zh) * 2015-05-07 2018-01-16 南京正大天晴制药有限公司 一种稳定的索氟布韦药物组合物及其制备方法
CN105168158B (zh) * 2015-08-18 2018-08-03 上海韬鸿化工科技有限公司 一种瑞舒伐他汀钙分散片及其制备方法
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
CN108245516B (zh) * 2017-11-09 2019-04-12 浙江京新药业股份有限公司 一种含瑞舒伐他汀钙的药物组合物及其制备方法
CN112274487A (zh) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 一种瑞舒伐他汀钙药物制剂
CN115317455B (zh) * 2022-08-17 2023-08-22 新发药业有限公司 一种药片含量均匀、易于溶出的瑞舒伐他汀钙片及其制备方法
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
JP4666855B2 (ja) * 1999-07-20 2011-04-06 スリーエム イノベイティブ プロパティズ カンパニー 消火組成物中でのフッ素化ケトンの使用法
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US20030031720A1 (en) * 2000-02-24 2003-02-13 Tobias Laich Method for producing pharmaceutical dosage forms
GB0111077D0 (en) * 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
AP2004003112A0 (en) * 2002-02-14 2004-09-30 Ranbaxy Lab Ltd Formulations of atorvastatin stabilised with alkali metal additions
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
SI21400A (sl) 2003-02-12 2004-08-31 LEK farmacevtska družba d.d. Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze
WO2005021511A1 (en) * 2003-08-27 2005-03-10 Hetero Drugs Limited A novel process for amorphous rosuvastatin calcium
MX2007009281A (es) * 2005-02-10 2007-09-25 Lufecycle Pharma As Composicion farmaceutica estable que comprende una combinacion de dosis fija de fenofibrato y un inhibidor de 3-hidroxi 3-metilglutaril-coenzima a reductasa.
US20070202159A1 (en) * 2006-02-02 2007-08-30 Mathur Rajeev S Pharmaceutical composition comprising stabilized statin particles

Also Published As

Publication number Publication date
AU2007298751A1 (en) 2008-03-27
EP2063868B1 (en) 2010-11-24
EP2063868A1 (en) 2009-06-03
DK2063868T3 (da) 2011-02-07
AR062874A1 (es) 2008-12-10
JP5534812B2 (ja) 2014-07-02
PT2063868E (pt) 2010-12-23
CA2662919A1 (en) 2008-03-27
HUP0600728A2 (en) 2008-06-30
US8221788B2 (en) 2012-07-17
ES2357263T3 (es) 2011-04-20
JO2641B1 (en) 2012-06-17
CA2662919C (en) 2013-04-30
SI2063868T1 (sl) 2011-03-31
CY1114533T1 (el) 2016-10-05
TW200829246A (en) 2008-07-16
HU227610B1 (en) 2011-09-28
ME01944B (me) 2011-08-31
DE602007010797D1 (de) 2011-01-05
PL2063868T3 (pl) 2011-05-31
AU2007298751B2 (en) 2013-05-02
CN101516349A (zh) 2009-08-26
US20090297599A1 (en) 2009-12-03
UA97489C2 (ru) 2012-02-27
WO2008035128A1 (en) 2008-03-27
ATE489078T1 (de) 2010-12-15
JP2010503723A (ja) 2010-02-04
RS51563B (en) 2011-08-31
TWI454265B (zh) 2014-10-01
HU0600728D0 (en) 2006-11-28
EA014451B1 (ru) 2010-12-30
HRP20110125T1 (hr) 2011-03-31

Similar Documents

Publication Publication Date Title
EA200970291A1 (ru) Фармацевтическая композиция, содержащая розувастатин кальция
RS52874B (en) THYOPHEN ANALYSIS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
RS54587B1 (en) IMINOTIADIAZINE-DIOXIDE COMPOUNDS AS BACE, MIXTURE, AND USE INHIBITORS
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
ATE517611T1 (de) Darreichungsform enthaltend oxycodon und naloxon
EA200602129A1 (ru) Новое применение пептидных соединений для лечения дискинезии
TN2012000458A1 (en) Uses of dgat1 inhibitors
PE20201496A1 (es) Composiciones y metodos para tratar anemia
NO20081636L (no) FAP - inhibitorer
EA200900213A1 (ru) Ингибиторы обратной транскриптазы вич (варианты), фармацевтическая композиция на их основе, способ ингибирования репликации ретровируса с их помощью и названные ингибиторы для изготовления лекарственного средства для ингибирования обратной транскриптазы вич и для лечения или профилактики инфекционного вич
EA200901319A1 (ru) Композиции для назального введения
RU2008139905A (ru) Фармацевтическая композиция для наружного применения
EA201490161A1 (ru) Соединения - ингибиторы сигналинга, опосредуемого рецептором notch
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
EA201391018A1 (ru) Препараты иммуносупрессантов
UA107967C2 (en) Pharmaceutical composition in the form of bilayer tablets which contain inhibitor of hmg-coa reductase inhibitor and irbesartan
EA200970041A1 (ru) Ингибиторы акт (протеинкиназы в)
EA200702282A1 (ru) Комбинация феррохина и производного артемизинина для лечения малярии
EA200970126A1 (ru) Способ получения прегабалина и его энантиомера
WO2008073332A3 (en) Creatine compositions for skin treatment
MY148393A (en) Malate salts, and polymorphs of (3s, 5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
TR201004464A2 (tr) Kemik erimesi için formülasyon.